The Initial Public Offering (IPO) of Corona Remedies Limited, a fast-growing, India-focused pharmaceutical formulation company, opens for public subscription today, December 8, 2025. The Ahmedabad-based company is raising capital through an Offer for Sale (OFS).
Here are five must-know details for investors considering subscribing to the issue:
1. Issue Dates and Listing Details
The subscription window for the Corona Remedies IPO will be open for three days:
- Opening Date: Monday, December 8, 2025
- Closing Date: Wednesday, December 10, 2025
- Allotment Finalization (Tentative): Thursday, December 11, 2025
- Tentative Listing Date: Monday, December 15, 2025 (on both the BSE and NSE).
2. Price Band and Minimum Lot Size
The company has set a high price band, reflective of its robust financial performance:
- Price Band: ₹1,008 to ₹1,062 per equity share.
- Face Value: ₹10 per share.
- Minimum Bid Lot: Retail investors must bid for a minimum of 14 shares (one lot).
- Minimum Retail Investment: At the upper price band, the minimum investment is ₹14,868.
3. Total Issue Size and Offer Structure (Pure OFS)
The IPO is entirely an Offer for Sale (OFS), meaning the company will not receive any funds from the issue:
- Total Issue Size: Approximately ₹655.37 Crore.
- Offer Type: The entire issue consists of an Offer for Sale of 61.71 lakh equity shares.
- Fund Utilization: Since it is a pure OFS, all proceeds will go to the selling shareholders (promoters and existing institutional investors like Sepia Investments and Anchor Partners), providing them with a partial exit.
4. Grey Market Premium (GMP) Indication
The Grey Market Premium (GMP) indicates a strong level of investor interest ahead of the official listing:
- Latest GMP: Varying reports suggest the GMP is around ₹330 per share (This is based on unofficial market speculation).
- Estimated Listing Price: Based on the upper price band, the shares are estimated to list around ₹1,392
Note: GMP is an unofficial indicator and not a reliable predictor of the actual listing price.
5. Financial Snapshot and Market Position
Corona Remedies is positioned as a high-growth player in the domestic pharmaceutical market:
- Growth Rate: The company is recognized as the second fastest-growing firm among the top 30 in the Indian Pharmaceutical Market (IPM) in terms of domestic sales (MAT June 2022 to MAT June 2025).
- Profitability: For the financial year ended March 31, 2025 (FY25), the company reported a Profit After Tax (PAT) of ₹149.43 crore on a revenue of ₹1,202.35 crore.
- Portfolio Focus: It focuses on branded pharmaceutical formulations across chronic and specialist therapeutic areas, including women's healthcare, cardio-diabetes, pain management, and urology.
